{"id":403,"date":"2026-02-19T00:46:22","date_gmt":"2026-02-18T15:46:22","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp\/research\/research-detail\/research-group-9\/"},"modified":"2026-02-19T00:46:22","modified_gmt":"2026-02-18T15:46:22","slug":"research-group-9","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/research\/research-detail\/research-group-9\/","title":{"rendered":"\u708e\u75c7\u6027\u8178\u75be\u60a3\uff08IBD)\u30b0\u30eb\u30fc\u30d7"},"content":{"rendered":"\n\n
\n
\n\n
\n
\n

\u708e\u75c7\u6027\u8178\u75be\u60a3\uff08IBD)\u30b0\u30eb\u30fc\u30d7<\/h2>\n <\/div>\n\n
\n
\n

\u30b0\u30eb\u30fc\u30d7\u30ea\u30fc\u30c0\u30fc\uff1a\u826f\u539f\u4e08\u592b<\/h2>\n

\u30b3\u30f3\u30bb\u30d7\u30c8\uff1a\u8178\u3092\u4e2d\u5fc3\u306b\u3057\u305f\u4f53\u5185\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u306e\u75c5\u614b\u89e3\u660e\u3068\u6cbb\u7642\u6226\u7565\u7814\u7a76<\/h3>\n

IBD\u30b0\u30eb\u30fc\u30d7\u3067\u306f\u3001\u8178\u3092\u5358\u72ec\u306e\u81d3\u5668\u3067\u306f\u306a\u304f\u3001\u5168\u8eab\u306e\u6052\u5e38\u6027\u3092\u652f\u3048\u308b\u300c\u60c5\u5831\u30cf\u30d6\u300d\u3068\u6349\u3048\u3066\u3044\u307e\u3059\u3002\u8178\u7c98\u819c\u3001\u514d\u75ab\u7cfb\u3001\u8178\u5185\u7d30\u83cc\u53e2\u3001\u795e\u7d4c\u7cfb\u306f\u76f8\u4e92\u306b\u60c5\u5831\u3092\u3084\u308a\u53d6\u308a\u3059\u308b\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u3092\u5f62\u6210\u3057\u3066\u304a\u308a\u3001\u75c5\u614b\u306f\u3053\u306e\u9023\u643a\u306e\u7834\u7dbb\u3068\u3057\u3066\u73fe\u308c\u308b\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u3001\u8102\u8cea\u3001\u7cd6\u9396\u3001\u8178\u5185\u7d30\u83cc\u4ee3\u8b1d\u7523\u7269\u306a\u3069\u306e\u5206\u5b50\u30ec\u30d9\u30eb\u306e\u89e3\u6790\u3092\u57fa\u76e4\u306b\u3001\u8178\u3068\u8178\u5185\u7d30\u83cc\u53e2\u3001\u8178\u3068\u4e2d\u67a2\u795e\u7d4c\u7cfb\u3068\u306e\u9023\u95a2\u306e\u4e2d\u3067\u708e\u75c7\u304c\u3069\u306e\u3088\u3046\u306b\u767a\u751f\u30fb\u5236\u5fa1\u3055\u308c\u308b\u304b\u306e\u89e3\u660e\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u5206\u5b50\u6a5f\u69cb\u306e\u7406\u89e3\u3092\u3001\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u958b\u767a\u3084\u6cbb\u7642\u6226\u7565\u306e\u6700\u9069\u5316\u3078\u3068\u3064\u306a\u3052\u308b\u30c8\u30e9\u30f3\u30b9\u30ec\u30fc\u30b7\u30e7\u30ca\u30eb\u7814\u7a76\u3092\u901a\u3058\u3001\u4f53\u5185\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u306e\u8996\u70b9\u304b\u3089\u75c5\u6c17\u306b\u30a2\u30d7\u30ed\u30fc\u30c1\u3059\u308b\u7cbe\u5bc6\u533b\u7642\u306e\u69cb\u7bc9\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n \"\u7814\u7a76\u6982\u8981\u56f3\"\n <\/div>\n <\/div>\n\n
\n

\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u306b\u3088\u308b\u708e\u75c7\u6027\u8178\u75be\u60a3(IBD)\u306e\u6cbb\u7642\u6226\u7565\u69cb\u7bc9<\/h3>\n

IBD\u3067\u306f\u591a\u69d8\u306a\u6cbb\u7642\u85ac\u304c\u4f7f\u7528\u53ef\u80fd\u3068\u306a\u308b\u4e00\u65b9\u3067\u3001\u3069\u306e\u60a3\u8005\u306b\u3069\u306e\u6cbb\u7642\u304c\u6700\u9069\u304b\u3092\u4e8b\u524d\u306b\u5224\u65ad\u3059\u308b\u3053\u3068\u306f\u4f9d\u7136\u3068\u3057\u3066\u96e3\u3057\u3044\u8ab2\u984c\u3067\u3059\u3002\u3053\u306e\u7814\u7a76\u3067\u306f\u3001\u8840\u4e2d\u306a\u3069\u306e\u4f53\u5185\u5206\u5b50\u3092\u7528\u3044\u3066\u4f53\u5185\u306e\u708e\u75c7\u72b6\u614b\u3084\u514d\u75ab\u5fdc\u7b54\u306e\u7279\u5fb4\u3092\u53ef\u8996\u5316\u3059\u308b\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u306e\u958b\u767a\u306b\u53d6\u308a\u7d44\u3093\u3067\u3044\u307e\u3059\u3002\u5206\u5b50\u30e1\u30ab\u30cb\u30ba\u30e0\u7814\u7a76\u3067\u5f97\u3089\u308c\u305f\u77e5\u898b\u3092\u57fa\u76e4\u3068\u3057\u3001\u708e\u75c7\u306e\u30bf\u30a4\u30d7\u3084\u75c5\u614b\u306e\u9055\u3044\u3092\u53cd\u6620\u3059\u308b\u6307\u6a19\u3092\u540c\u5b9a\u3059\u308b\u3053\u3068\u3067\u3001\u6cbb\u7642\u53cd\u5fdc\u6027\u306e\u4e88\u6e2c\u3084\u6cbb\u7642\u9078\u629e\u306e\u6700\u9069\u5316\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u57fa\u790e\u7814\u7a76\u3068\u81e8\u5e8a\u30c7\u30fc\u30bf\u3092\u7d71\u5408\u3057\u305f\u30c8\u30e9\u30f3\u30b9\u30ec\u30fc\u30b7\u30e7\u30ca\u30eb\u7814\u7a76\u3068\u3057\u3066\u3001\u500b\u5225\u5316\u533b\u7642\u306e\u5b9f\u73fe\u306b\u8ca2\u732e\u3059\u308b\u3053\u3068\u3092\u76ee\u6a19\u3068\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n

IBD\u767a\u75c7\u30fb\u5897\u60aa\u306e\u5206\u5b50\u30e1\u30ab\u30cb\u30ba\u30e0\u7814\u7a76<\/h3>\n

IBD\u3067\u306f\u3001\u8178\u7c98\u819c\u306b\u304a\u3051\u308b\u514d\u75ab\u5fdc\u7b54\u306e\u5236\u5fa1\u304c\u7834\u7dbb\u3057\u3001\u6162\u6027\u7684\u306a\u708e\u75c7\u304c\u6301\u7d9a\u3057\u307e\u3059\u3002\u672c\u7814\u7a76\u3067\u306f\u3001\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u3060\u3051\u3067\u306a\u304f\u3001\u8102\u8cea\u30e1\u30c7\u30a3\u30a8\u30fc\u30bf\u30fc\u3084\u7cd6\u9396\u4fee\u98fe\u3068\u3044\u3063\u305f\u5206\u5b50\u306b\u3082\u7740\u76ee\u3057\u3001\u708e\u75c7\u306e\u5f37\u3055\u3084\u6027\u8cea\u3092\u6c7a\u5b9a\u3059\u308b\u5206\u5b50\u6a5f\u69cb\u3092\u591a\u89d2\u7684\u306b\u89e3\u6790\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u5206\u5b50\u306f\u7d30\u80de\u9593\u3067\u60c5\u5831\u3092\u4f1d\u3048\u308b\u91cd\u8981\u306a\u30b7\u30b0\u30ca\u30eb\u3067\u3042\u308a\u3001\u305d\u306e\u8cea\u7684\u5909\u5316\u304c\u708e\u75c7\u306e\u6301\u7d9a\u3084\u7d44\u7e54\u969c\u5bb3\u306e\u9032\u5c55\u306b\u95a2\u4e0e\u3059\u308b\u3068\u8003\u3048\u3089\u308c\u307e\u3059\u3002\u5206\u5b50\u30ec\u30d9\u30eb\u306e\u89e3\u6790\u3092\u901a\u3058\u3066\u3001\u8178\u708e\u304c\u3069\u306e\u3088\u3046\u306b\u8d77\u3053\u308a\u3001\u3069\u306e\u3088\u3046\u306b\u5897\u5e45\u30fb\u5236\u5fa1\u3055\u308c\u308b\u306e\u304b\u3092\u89e3\u660e\u3057\u3001\u65b0\u305f\u306a\u6cbb\u7642\u6a19\u7684\u306e\u540c\u5b9a\u3084\u75c5\u614b\u7406\u89e3\u306e\u6df1\u5316\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059<\/p>\n <\/div>\n\n

\n

\u795e\u7d4c\u7cfb\u3092\u4ecb\u3057\u305f\u8178\u708e\u5236\u5fa1\u3068\u7cbe\u795e\u75c7\u72b6\u306b\u95a2\u3059\u308b\u8133\u8178\u76f8\u95a2\u7814\u7a76<\/h3>\n

\u8178\u306b\u306f\u8133\u306b\u3082\u5339\u6575\u3059\u308b\u9ad8\u5ea6\u306b\u767a\u9054\u3057\u305f\u795e\u7d4c\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u304c\u5b58\u5728\u3057\u3001\u4e2d\u67a2\u795e\u7d4c\u7cfb\u3068\u53cc\u65b9\u5411\u306b\u60c5\u5831\u3092\u3084\u308a\u53d6\u308a\u3057\u3066\u3044\u307e\u3059\u3002\u672c\u7814\u7a76\u3067\u306f\u3001\u8178\u306e\u708e\u75c7\u304c\u795e\u7d4c\u7cfb\u306b\u4e0e\u3048\u308b\u5f71\u97ff\u3001\u3055\u3089\u306b\u795e\u7d4c\u7cfb\u304c\u8178\u708e\u3092\u3069\u306e\u3088\u3046\u306b\u5236\u5fa1\u3057\u3066\u3044\u308b\u304b\u3068\u3044\u3046\u5206\u5b50\u30fb\u795e\u7d4c\u57fa\u76e4\u3092\u89e3\u6790\u3059\u308b\u57fa\u790e\u7814\u7a76\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002\u540c\u6642\u306b\u3001IBD\u60a3\u8005\u306b\u307f\u3089\u308c\u308b\u6291\u3046\u3064\u3084\u4e0d\u5b89\u306a\u3069\u306e\u7cbe\u795e\u75c7\u72b6\u306b\u7740\u76ee\u3057\u3001\u8178\u306e\u708e\u75c7\u72b6\u614b\u3068\u5fc3\u7406\u75c7\u72b6\u3068\u306e\u95a2\u9023\u3092\u81e8\u5e8a\u7684\u306b\u8a55\u4fa1\u3057\u3066\u3044\u307e\u3059\u3002\u8178\u304b\u3089\u306e\u30b7\u30b0\u30ca\u30eb\u304c\u795e\u7d4c\u7cfb\u3092\u4ecb\u3057\u3066\u5168\u8eab\u306b\u5f71\u97ff\u3092\u53ca\u307c\u3059\u4ed5\u7d44\u307f\u3092\u89e3\u660e\u3057\u3001\u8178\u3068\u8133\u3092\u542b\u3080\u81d3\u5668\u9593\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u306e\u8996\u70b9\u304b\u3089\u3001\u8178\u708e\u3068\u7cbe\u795e\u75c7\u72b6\u306e\u53cc\u65b9\u306b\u30a2\u30d7\u30ed\u30fc\u30c1\u3059\u308b\u65b0\u305f\u306a\u6cbb\u7642\u6226\u7565\u306e\u53ef\u80fd\u6027\u3092\u63a2\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n <\/div>\n\n

\n

\u8178\u5185\u7d30\u83cc\u53e2\u7814\u7a76\u3068\u8178\u5185\u7d30\u83cc\u53e2\u79fb\u690d\u7642\u6cd5\uff08FMT\uff09\u306e\u5b9f\u88c5<\/h3>\n

\u8178\u5185\u7d30\u83cc\u53e2\u306f\u5bbf\u4e3b\u3068\u306f\u7570\u306a\u308b\u907a\u4f1d\u60c5\u5831\u3092\u6301\u3061\u306a\u304c\u3089\u3001\u514d\u75ab\u5fdc\u7b54\u3084\u4ee3\u8b1d\u6a5f\u80fd\u306e\u8abf\u7bc0\u306b\u6df1\u304f\u95a2\u4e0e\u3059\u308b\u201c\u6a5f\u80fd\u7684\u81d3\u5668\u201d\u3068\u8003\u3048\u3089\u308c\u3066\u3044\u307e\u3059\u3002\u672c\u7814\u7a76\u3067\u306f\u3001\u8178\u5185\u7d30\u83cc\u3068\u8178\u7c98\u819c\u3068\u306e\u76f8\u4e92\u4f5c\u7528\u306b\u6ce8\u76ee\u3057\u3001\u7d30\u83cc\u7531\u6765\u4ee3\u8b1d\u7523\u7269\u3084\u514d\u75ab\u7d30\u80de\u3068\u306e\u95a2\u4fc2\u3092\u57fa\u790e\u7684\u306b\u89e3\u6790\u3057\u3066\u3044\u307e\u3059\u3002\u8178\u5185\u7d30\u83cc\u53e2\u306e\u69cb\u6210\u5909\u5316\uff08\u30c7\u30a3\u30b9\u30d0\u30a4\u30aa\u30fc\u30b7\u30b9\uff09\u304c\u8178\u708e\u306e\u767a\u75c7\u3084\u5897\u60aa\u306b\u3069\u306e\u3088\u3046\u306b\u95a2\u4e0e\u3059\u308b\u304b\u3092\u660e\u3089\u304b\u306b\u3059\u308b\u3068\u3068\u3082\u306b\u3001\u3053\u308c\u3089\u306e\u77e5\u898b\u3092\u8178\u5185\u7d30\u83cc\u53e2\u79fb\u690d\uff08FMT\uff09\u3078\u3068\u5fdc\u7528\u3057\u3066\u3044\u307e\u3059\u3002FMT\u3092\u5b89\u5168\u304b\u3064\u6709\u52b9\u306b\u5b9f\u65bd\u3059\u308b\u305f\u3081\u306e\u4f53\u5236\u6574\u5099\u3068\u52b9\u679c\u8a55\u4fa1\u3092\u9032\u3081\u3001\u5fae\u751f\u7269\u53e2\u4ecb\u5165\u306b\u57fa\u3065\u304f\u65b0\u3057\u3044\u6cbb\u7642\u6226\u7565\u306e\u78ba\u7acb\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n <\/div>\n <\/section>\n\n

\n

\u5c06\u6765\u5c55\u671b\uff1a\u5206\u5b50\u6a5f\u69cb\u306e\u89e3\u660e\u304b\u3089\u60a3\u8005\u500b\u5225\u306e\u6cbb\u7642\u6700\u9069\u5316\u3078<\/h3>\n

\u3053\u308c\u3089\u306e\u7814\u7a76\u3067\u5f97\u3089\u308c\u308b\u5206\u5b50\u6a5f\u69cb\u306e\u7406\u89e3\u306f\u3001\u8a3a\u65ad\u3084\u6cbb\u7642\u9078\u629e\u306e\u9ad8\u5ea6\u5316\u306b\u3064\u306a\u304c\u308b\u3068\u671f\u5f85\u3055\u308c\u307e\u3059\u3002\u708e\u75c7\u306e\u8cea\u3092\u53cd\u6620\u3059\u308b\u8840\u4e2d\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u306e\u78ba\u7acb\u306b\u3088\u308a\u75c5\u614b\u3092\u53ef\u8996\u5316\u3057\u3001\u60a3\u8005\u3054\u3068\u306b\u6700\u9069\u306a\u6cbb\u7642\u6cd5\u3092\u9078\u629e\u3059\u308b\u500b\u5225\u5316\u533b\u7642\u306e\u5b9f\u73fe\u3092\u76ee\u6307\u3057\u307e\u3059\u3002\u3055\u3089\u306b\u3001\u8c4a\u5bcc\u306a\u8a3a\u7642\u7d4c\u9a13\u304b\u3089\u5f97\u3089\u308c\u308b\u91cd\u8981\u306a\u30af\u30ea\u30cb\u30ab\u30eb\u30af\u30a8\u30b9\u30c1\u30e7\u30f3\u3092\u51fa\u767a\u70b9\u3068\u3057\u3001\u57fa\u790e\u7814\u7a76\u306b\u3088\u308b\u65b0\u305f\u306a\u7814\u7a76\u30b7\u30fc\u30ba\u306e\u5275\u51fa\u3068\u75be\u60a3\u30e1\u30ab\u30cb\u30ba\u30e0\u306e\u89e3\u660e\u3092\u9032\u3081\u307e\u3059\u3002\u3053\u308c\u3089\u306e\u77e5\u898b\u3092\u30c8\u30e9\u30f3\u30b9\u30ec\u30fc\u30b7\u30e7\u30ca\u30eb\u7814\u7a76\u3078\u3068\u63a5\u7d9a\u3057\u3001\u8178\u5185\u7d30\u83cc\u53e2\u79fb\u690d\uff08FMT\uff09\u306a\u3069\u306e\u4ecb\u5165\u7814\u7a76\u3092\u901a\u3058\u3066\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u3078\u5c55\u958b\u3057\u307e\u3059\u3002\u57fa\u790e\u3068\u81e8\u5e8a\u3092\u5faa\u74b0\u3055\u305b\u308b\u7814\u7a76\u4f53\u5236\u306b\u3088\u308a\u3001\u5b9f\u969b\u306e\u60a3\u8005\u533b\u7642\u3078\u306e\u9084\u5143\u3092\u52a0\u901f\u3057\u3066\u3044\u304d\u307e\u3059\u3002<\/p>\n <\/section>\n\n

\n

\u3010\u4e3b\u8981\u8ad6\u6587\u3011<\/h3>\n
    \n
  1. Yoshihara T, Shinzaki S, Amano T, Iijima H, Takehara T, Inoue N, Uchino M, Esaki M, Kobayashi T, Saruta M, Sugimoto K, Nakamura S, Hata K, Hirai F, Hiraoka S, Fujii T, Matsuura M, Matsuoka K, Watanabe K, Nakase H, Watanabe M. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn’s disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021 Jul;36(7):1744-1753. doi: 10.1111\/jgh.15401. Epub 2021 Feb 3. PMID: 33450096.<\/li>\n
  2. Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, Yoshihara T, Iwatani S, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Iijima H, Takehara T. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Sci Rep. 2022 Mar 29;12(1):5324. doi: 10.1038\/s41598-022-09455-8. PMID: 35351986; PMCID: PMC8964802.<\/li>\n
  3. Yoshihara T, Amano T, Shinzaki S, Tsujii Y, Asakura A, Tashiro T, Tani M, Otake-Kasamoto Y, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Kitamura T, Kato M, Tsujii Y, Inoue T, Iijima H, Hayashi Y, Takehara T. Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching. Sci Rep. 2025 Jan 2;15(1):68. doi: 10.1038\/s41598-024-77365-y. PMID: 39747885; PMCID: PMC11696101.<\/li>\n
  4. Yoshihara T, Shinzaki S, Kawai S, Fujii H, Iwatani S, Yamaguchi T, Araki M, Hiyama S, Inoue T, Hayashi Y, Watabe K, Iijima H, Takehara T. Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn’s Disease. Inflamm Bowel Dis. 2017 Dec;23(12):2172-2179. doi: 10.1097\/MIB.0000000000001260. PMID: 28945638.<\/li>\n
  5. \u3010\u708e\u75c7\u6027\u8178\u75be\u60a3(IBD)\u8a3a\u7642\u306e\u73fe\u6cc1\u3011IBD\u306e\u75be\u60a3\u6d3b\u52d5\u6027\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0 \u65e5\u672c\u5185\u79d1\u5b66\u4f1a\u96d1\u8a8c 2025\u5e74\u3000\u826f\u539f\u4e08\u592b\u3001\u6797\u7fa9\u4eba\u3001\u7af9\u539f\u5fb9\u90ce<\/li>\n
  6. Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021 Jun;56(6):489-526. doi: 10.1007\/s00535-021-01784-1. Epub 2021 Apr 22. PMID: 33885977; PMCID: PMC8137635.<\/li>\n
  7. \u708e\u75c7\u6027\u8178\u75be\u60a3\uff08IBD\uff09\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32020\u3000\u4f5c\u6210\u59d4\u54e1 \u65b0\u5d0e\u4fe1\u4e00\u90ce\u3000\u4f5c\u6210\u5354\u529b\u8005 \u826f\u539f\u4e08\u592b<\/li>\n
  8. Iwatani S, Iijima H, Otake Y, Amano T, Tani M, Yoshihara T, Tashiro T, Tsujii Y, Inoue T, Hayashi Y, Takeda K, Hayashi A, Fujita S, Shinzaki S, Takehara T. Novel mass spectrometry-based comprehensive lipidomic analysis of plasma from patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2020 Aug;35(8):1355-1364. doi: 10.1111\/jgh.15067. Epub 2020 Apr 23. PMID: 32285970.<\/li>\n
  9. Otake-Kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T. Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response. J Exp Med. 2022 Jul 4;219(7):e20211291. doi: 10.1084\/jem.20211291. Epub 2022 May 24. PMID: 35608941; PMCID: PMC9134096.<\/li>\n
  10. Serada S, Fujimoto M, Terabe F, Iijima H, Shinzaki S, Matsuzaki S, Ohkawara T, Nezu R, Nakajima S, Kobayashi T, Plevy SE, Takehara T, Naka T. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 2012 Nov;18(11):2169-79. doi: 10.1002\/ibd.22936. Epub 2012 Feb 28. PMID: 22374925.<\/li>\n
  11. Shinzaki S, Matsuoka K, Iijima H, Mizuno S, Serada S, Fujimoto M, Arai N, Koyama N, Morii E, Watanabe M, Hibi T, Kanai T, Takehara T, Naka T. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. J Crohns Colitis. 2017 Jan;11(1):84-91. doi: 10.1093\/ecco-jcc\/jjw132. Epub 2016 Jul 27. Erratum in: J Crohns Colitis. 2019 Dec 10;13(12):1590. doi: 10.1093\/ecco-jcc\/jjz100. PMID: 27466171; PMCID: PMC5175492.<\/li>\n
  12. Shinzaki S, Matsuoka K, Tanaka H, Takeshima F, Kato S, Torisu T, Ohta Y, Watanabe K, Nakamura S, Yoshimura N, Kobayashi T, Shiotani A, Hirai F, Hiraoka S, Watanabe M, Matsuura M, Nishimoto S, Mizuno S, Iijima H, Takehara T, Naka T, Kanai T, Matsumoto T. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J Gastroenterol. 2021 Jun;56(6):560-569. doi: 10.1007\/s00535-021-01793-0. Epub 2021 May 3. PMID: 33942166; PMCID: PMC8137624.<\/li>\n
  13. Amano T, Yoshihara T, Shinzaki S, Sakakibara Y, Yamada T, Osugi N, Hiyama S, Murayama Y, Nagaike K, Ogiyama H, Yamaguchi T, Arimoto Y, Kobayashi I, Kawai S, Egawa S, Kizu T, Komori M, Tsujii Y, Asakura A, Tashiro T, Tani M, Otake-Kasamoto Y, Uema R, Kato M, Tsujii Y, Inoue T, Yamada T, Kitamura T, Yonezawa A, Iijima H, Hayashi Y, Takehara T. Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease. Sci Rep. 2024 Nov 29;14(1):29755. doi: 10.1038\/s41598-024-80285-6. PMID: 39613813; PMCID: PMC11607305.<\/li>\n
  14. Tashiro T, Shinzaki S, Yoshihara T, Tsujii Y, Asakura A, Amano T, Tani M, Otake-Kasamoto Y, Uema R, Tsujii Y, Inoue T, Ogino T, Iijima H, Hayashi Y, Takehara T. Leucine-rich Alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn’s disease. Sci Rep. 2025 Mar 16;15(1):9031. doi: 10.1038\/s41598-025-93831-7. PMID: 40091130; PMCID: PMC11911423.<\/li>\n
  15. Otake-Kasamoto Y, Shinzaki S, Hiyama S, Tashiro T, Amano T, Tani M, Yoshihara T, Inoue T, Kawai S, Yoshii S, Tsujii Y, Hayashi Y, Iijima H, Takehara T. Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial. PLoS One. 2023 Aug 17;18(8):e0290329. doi: 10.1371\/journal.pone.0290329. PMID: 37590283; PMCID: PMC10434883.<\/li>\n
  16. Otake-Kasamoto Y, Yoshihara T, Shinzaki S, Yamada T, Ogawa H, Sakakibara Y, Hiyama S, Tsujii Y, Asakura A, Tashiro T, Amano T, Tani M, Uema R, Tsujii Y, Inoue T, Iijima H, Hayashi Y, Takehara T. Safety and Effectiveness of Oral Budesonide after Endoscopic Balloon Dilation in Patients with Crohn’s Disease: A Multicenter Prospective Intervention Study. Inflamm Intest Dis. 2025 Jul 30;10(1):254-264. doi: 10.1159\/000547608. PMID: 41537188; PMCID: PMC12799228.<\/li>\n
  17. Fujii H, Shinzaki S, Iijima H, Wakamatsu K, Iwamoto C, Sobajima T, Kuwahara R, Hiyama S, Hayashi Y, Takamatsu S, Uozumi N, Kamada Y, Tsujii M, Taniguchi N, Takehara T, Miyoshi E. Core Fucosylation on T Cells, Required for Activation of T-Cell Receptor Signaling and Induction of Colitis in Mice, Is Increased in Patients With Inflammatory Bowel Disease. Gastroenterology. 2016 Jun;150(7):1620-1632. doi: 10.1053\/j.gastro.2016.03.002. Epub 2016 Mar 8. PMID: 26965517.<\/li>\n
  18. Iwatani S, Shinzaki S, Amano T, Otake Y, Tani M, Yoshihara T, Tsujii Y, Hayashi Y, Inoue T, Okuzaki D, Mizushima T, Miyoshi E, Iijima H, Takehara T. Oligosaccharide-dependent anti-inflammatory role of galectin-1 for macrophages in ulcerative colitis. J Gastroenterol Hepatol. 2020 Dec;35(12):2158-2169. doi: 10.1111\/jgh.15097. Epub 2020 Jul 6. PMID: 32424849.<\/li>\n
  19. Tani M, Shinzaki S, Asakura A, Tashiro T, Amano T, Otake-Kasamoto Y, Yoshihara T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Motooka D, Nakamura S, Iijima H, Takehara T. Seasonal variations in gut microbiota and disease course in patients with inflammatory bowel disease. PLoS One. 2023 Apr 18;18(4):e0283880. doi: 10.1371\/journal.pone.0283880. PMID: 37071621; PMCID: PMC10112787.<\/li>\n
  20. Kusakabe S, Kurashige R, Fukushima K, Shimizu K, Yoshihara T, Motooka D, Nakamura S, Kurashige M, Nakata K, Hino A, Kasahara H, Ueda T, Fujita J, Hosen N, Takehara T, Oda J. Fecal microbiota transplantation for Crohn’s disease-like intestinal lesions arising after allogeneic stem cell transplantation. Int J Hematol. 2025 Nov;122(5):771-777. doi: 10.1007\/s12185-025-04049-2. Epub 2025 Aug 28. PMID: 40866789.<\/li>\n <\/ol>\n <\/section>\n\n <\/div>\n<\/main>\n","protected":false},"excerpt":{"rendered":"

    \u708e\u75c7\u6027\u8178\u75be\u60a3\uff08IBD)\u30b0\u30eb\u30fc\u30d7 \u30b0\u30eb\u30fc\u30d7\u30ea\u30fc\u30c0\u30fc\uff1a\u826f\u539f\u4e08\u592b \u30b3\u30f3\u30bb\u30d7\u30c8\uff1a\u8178\u3092\u4e2d\u5fc3\u306b\u3057\u305f\u4f53\u5185\u30cd\u30c3\u30c8\u30ef\u30fc\u30af\u306e\u75c5\u614b\u89e3\u660e\u3068\u6cbb\u7642\u6226\u7565\u7814\u7a76 IBD\u30b0\u30eb\u30fc\u30d7\u3067\u306f\u3001\u8178\u3092\u5358\u72ec\u306e\u81d3\u5668\u3067\u306f\u306a\u304f\u3001\u5168\u8eab\u306e\u6052\u5e38\u6027\u3092\u652f\u3048\u308b\u300c\u60c5\u5831\u30cf\u30d6\u300d\u3068\u6349\u3048\u3066\u3044\u307e\u3059\u3002 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":124,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"folder":[14],"class_list":["post-403","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/comments?post=403"}],"version-history":[{"count":1,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/403\/revisions"}],"predecessor-version":[{"id":411,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/403\/revisions\/411"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/pages\/124"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/media?parent=403"}],"wp:term":[{"taxonomy":"folder","embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gh\/wp-json\/wp\/v2\/folder?post=403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}